The general misconception that the polyamines putrescine, spermidine, and spermine ( Fig. 1 ) are cellular degradation products initially hampered research within this field. During the last decade, however, polyamine research has truly burgeoned, and as a result many important roles have been discovered. In fact, it now appears that cells depend on polyamines for many of their life processes. Due to the multitude of new findings, I am compelled to limit the present discussion. The detailed aspects of polyamine biochemistry and physiology may be found in more comprehensive reviews and in proceedings of recent meetings (l-3, 5, 6).
3OO-Year-old history
The history of the polyamines began in 1678 ported to the newly formed Royal Society of London in the famous letter in which he first described spermatozoa. The name spermine was given to the base in 1888 by Ladenburg and Abel, but its chemical nature remained unclear until the EJZOs, when Rosenheim and his collaborators finally confirmed the structure by synthesis. In addition, they discovered a related base, which they named spermidine.
In 1885 two other related bases were isolated from decomposing animal material by Brieger, and in 1886 Ladenburg confirmed their structures by synthesis. They were named putrescine and cadaverine because of their origin and foul smell of putrefaction.
Occurrence
The polyamines are found not only in semen and in decomposing animal material-they are ubiquitous in nature. Putrescine and spermidine are synthesized in all cells, but spermine only in eukaryotic cells. Viruses and physiological fluids also contain polyamines, but these are derived from cells.
Properties
At a physiological pH, putrescine, spermidine, and spermine are protonated and possess two, three, and four positive charges, respectively (cf. Fig. 1 the initial and rate-limiting enzyme in polyamine biosynthesis in mammalian and many other eukaryotic cells (Fig. 2) . These cells have no other means of putrescine formation, whereas prokaryotic cells possess an additional pathway ( Fig. 2 ). Putrescine is converted to the higher polyamines spermidine and spermine by successive addition of aminopropyl groups derived from decarboxylated S-adenosylmethionine. These reactions are catalyzed by spermidine synthase and spermine synthase, respectively. Prokaryotes lack spermine synthase and, as a consequence, spermine. The formation of the aminopropyl group donor is catalyzed by S-adenosylmethionine decarboxylase.
ODC, a highly regulated enzyme ODC is a pyridoxal Y-phosphatedependent enzyme with an extremely short half-life. It may be as short as 5-15 min. This means that ODC is synthesized and degraded at a higher rate than are other enzymes. The short half-life enables cells to change their polyamine levels rapidly in response to various stimuli. In fact, ODC has remarkable FIGURE 2. Polyamine biosynthetic pathways: 1) arginine decarboxylase and 2) agmatine ureohydrolase (prokaryotes and plants); 3) arginase (eukaryotes); 4) ornithine decarboxylase and 5) spermidine synthase (pro-and eukaryotes); 6) spermine synthase (eukaryotes); 7) Sudenosylmethionine synthetase and 8) S-adenosylmethionine decarboxylase (pro-and eukaryotes). inducibility and may be stimulated several hundredfold by a wide variety of physiological and pharmacological agents (growth factors, hormones, tumor promoters, etc.). Nevertheless, it constitutes an exceedingly small fraction of the cellular protein content, and to isolate the homogeneous liver enzyme, a 7OO,UOO-fold purification was necessary. Cloning a gene that encodes a low-abundance protein such as ODC may seem an impossible task. Nevertheless, cDNA encoding mammalian ODC has been synthesized and cloned into plasmids. The problem of low abundance was overcome by using ODC-overproducing cell mutants and tissues as the source of enzyme.
The ODC activity seems to be regulated at a great many levels, i.e., by changes in mRNA synthesis and stability, by changes in the rates of synthesis and degradation of the enzyme, by production of macromolecular activators and inhibitors, by posttranslational modifications, and so on. With the recent isolation of cDNA clones encoding ODC and the cloning of the ODC gene, it has now become possible to explore further the molecular basis of ODC regulation.
Correlations to important cellular activities
The activities of the polyamine biosynthetic enzymes and the concentrations of the polyamines are elevated in rapidly proliferating tissues and increase abruptly when growth and differentiation are induced. Activation of polyamine biosynthesis usually precedes DNA, RNA, and protein synthesis, and in cell-free systems physiological concentrations of the polyamines stimulate many of the reactions involved in the synthesis of nucleic acids and proteins, These findings clearly indicate a role for the polyamines in cell growth and differentiation but do not provide any direct and conclusive evidence.
The obvious method of determining the physiological significance of the polyamines, and more specifically in which regulatory processes they may be involved, is by analyzing the consequences of specific depletion of the cellular polyamine
of inhibitors that specifically interfere with the polyamine biosynthetic enzymes. I will discuss only the latter approach, first because the limited amount of data that have been obtained using mammalian cell mutants agrees with the results of studies using specific inhibitors, and second because, in addition to providing information about polyamine function, specific inhibitors may have clinical utility.
Suicidal inhibition of ODC
The fact that ODC catalyzes the initial and rate-limiting step in polyamine synthesis makes it appropriate as a prime target of inhibitors.,By incorporating a latent reactive functionality (e.g., a fluorinated methyl group) into the natural substrate (ornithine) or product (putrescine), a variety of "suicide inhibitors"
(enzyme-activated irreversible inhibitors) of ODC have been obtained by investigators at the Merrell Dow Research Institute, Strasbourg, France. pL-a-Difluoromethylornithine (DFMO) is the most frequently used ODC inhibitor.
DFMO is highly specific because only ODC can decarboxylate, and thus activate, this substrate analogue. After the enzymatic decarboxylation, DFMO binds irreversibly to the active site of ODC, thus eradicating its catalytic capacity. By inhibiting 'the ODC activity, DFMO treatment causes cellular depletion of putrescine and spermidine but usually not of spermine.
The specificity of DFMO may be confirmed by observation of antagonism or reversal by low concentrations of putrescine, spermidine, and spermine.
Since DFMO is not actively transported into cells it must be used in large quantities. This has presented no problem because DFMO is surprisingly nontoxic. Nevertheless, several other suicide inhibitors have been synthesized, in the hope that some of these will prove to be more potent and longer acting than DFMO.
Because of its selectivity, DFMO Volume 1 /February 1986 NIPS may be used as a probe to delineate the effects of polyamine depletion in animals.
In view of the findings made thus far, it seems likely that DFMO might even become useful in the treatment of human diseases.
Early embryonic development
Early embryogenesis in animals is characterized by an increased rate of polyamine synthesis. Inhibition of this increase by DFMO treatment suppresses RNA and protein synthesis and prevents development beyond the stage of gastrulation, the event at which the fates of the main cell lineages are determined.
The developmental arrest appears to be due to the fact that polyamine depletion causes inhibition of the synthesis of all RNA species. This general suppression of transcription is probably the cause of inhibition of protein synthesis. The effects observed on mammalian development suggest that DFMO could be used as an abortifacient in domestic animals.
Cell growth and proliferation
All cells, normal as well as neoplastic, require an adequate concentration of polyamines to grow and divide at an optimal rate. When cells in culture are depleted of polyamines by DFMO treatment, their progression through the cell cycle is slowed and sometimes arrested. This cytostatic (rather than cytotoxic) effect of DFMO (even at high concentrations) has been observed for the large majority of cell lines. One exception to this rule, however, is that DFMO exerts a cytotoxic effect on small-cell lung carcinoma.
Even though DFMO treatment causes significant antitumor effects in numerous rodents, clinical studies of DFMO in patients with cancer have failed to demonstrate unequivocally an antitumor effect. Nevertheless, in combination with another polyamine synthesis inhibitor, a marked anticancer effect has been demonstrated in cases of childhood leukemia. Striking effects recently observed in a mouse melanoma indicate that combination therapy with interferon may prove effective. Tolerance of DFMO has been excellent and serious toxicity uncommon. Thrombocytopenia, anemia, and hearing loss have been reported, but these side effects reversed when drug therapy was discontinued.
Cell differentiation An increased rate of polyamine synthesis is associated with cell differentiation.
Accordingly, polyamine synthesis inhibition prevents the expression of differentiated phenotypes in many experimental models of differentiation, e.g., hormone-induced mammary gland, chondrocytes, myoblasts, and fibroblasts. In all cases, provision of exogenous polyamines replenishes their intracellular levels and reverses the antidifferentiative effects. The apparent conclusion from these experiments would seem to be that differentiation depends on the presence of sufficiently large polyamine pools in the cells. However, as will be seen below, there are exceptions to this rule. The effect of polyamine depletion on these tumor cells is contrary to that observed for normal cells. There is presently no explanation for the differences, but the finding may be a consequence of the basic differences in control mechanisms between tumor cells and normal cells. That polyamine depletion also induces morphological and functional differentiation in cultures of two other tumor cell lines, namely neuroblastoma and melanoma cells, is consistent with this idea.
In polyamine-depleted teratocarcinema stem cell cultures, differentiation is preceded by growth arrest in the G1 phase of the cell cycle, the phase preceding DNA replication. The exit from the cell cycle in G1 is probably an absolute requirement for induction of the. progressive changes in gene expression that are associated with differentiation. The fact that DFMO blocks teratocarcinoma stem cell proliferation and induces terminal differentiation of these highly malignant cells, yet exhibits minimal toxicity, suggests an exciting alternative to cytotoxic therapy of these germ cell tumors. of DFMO to the mosquitoes (in a sugar solution or in blood meals from DFMOtreated mice).
In studies of infected mice it has been shown that the curative action of DFMO is due specifically to ODC inhibition and polyamine depletion in the parasitic protozoa.
DFMO treatment inhibits growth in culture of another human pathogenic protozoan, Giardia Jam blia, which causes an intestinal disease called giardiasis. Moreover, DFMO has recently been found effective in the treatment of Pneumocystis carinii, an opportunistic protozoan infection in patients with acquired immune deficiency syndrome (AIDS).
of the extraordinary ability of the polyamines to induce Z-DNA conformation, which is apparently 3. formed specifically in transcriptional enhancer segments, the probable entrance sites for RNA polym-4 ' erases. A similar mechanism may operate in DNA replication and may explain the suppression of DNA synthesis in polyamine-depleted cells.
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